Literature DB >> 21622288

Mother knows best: lessons from fetomaternal tolerance applied to cancer immunity.

Shernan G Holtan1, Douglas J Creedon.   

Abstract

Failure of the immune system to recognize and eradicate tumor cells has deadly consequences. It is possible that the normal host response to the inflammatory environment created by many cancers - the body's natural attempt at wound repair and restoration of tissue integrity - is one of counter-regulation that paradoxically favors tumor growth. A physiologic condition where this situation is favorable (and even required) is that of normal pregnancy, where blastocyst implantation creates endometrial inflammation, and the maternal response in turn supports angiogenesis and tolerance required for placentation. Lack of such inflammation and resultant maternal immunologic engagement can lead to serious pregnancy complications including fetal loss, highlighting how important the fetomaternal immunologic dialogue is for survival. Here, we describe how the dynamics of fetomaternal tolerance can help disentangle complex cancer/host immunologic interactions and provide new avenues for immunologic reconstitution in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622288     DOI: 10.2741/243

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  3 in total

Review 1.  Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma.

Authors:  Elizabeth Ann L Enninga; Shernan G Holtan; Douglas J Creedon; Roxana S Dronca; Wendy K Nevala; Simona Ognjanovic; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 2.  Personalized therapy for metastatic melanoma: could timing be everything?

Authors:  Roxana S Dronca; Alexey A Leontovich; Wendy K Nevala; Svetomir N Markovic
Journal:  Future Oncol       Date:  2012-11       Impact factor: 3.404

3.  IDO1 is an Integral Mediator of Inflammatory Neovascularization.

Authors:  Arpita Mondal; Courtney Smith; James B DuHadaway; Erika Sutanto-Ward; George C Prendergast; Arturo Bravo-Nuevo; Alexander J Muller
Journal:  EBioMedicine       Date:  2016-11-09       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.